Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,108.40
(
-0.41%
)
US TECH 100
26,203.20
(
0.00%
)
Dow Jones
49,310.32
(
-0.36%
)
Brent Oil
100.82
(
-0.38%
)
Bitcoin
78,197.86
(
-0.10%
)
News Focus
News Focus
Post# of 257441
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

acgood

Send PM Follow Ignore
Followers 17
Posts 1093
Boards Moderated 0
Alias Born 05/12/2007

acgood

Re: mcbio post# 140729

Thursday, 04/26/2012 1:37:13 PM

Thursday, April 26, 2012 1:37:13 PM

Post# of 257441
1q12 Promacta sales seem disappointing to me unless there is a big currency issue with the USD sales comparisons. Especially given Nplate performance reported in this thread. AMGN has had advantages n the US from being a biologic, but previously the ROW performance had been more impressive for GSK. I assume no discussion on the conference call?

Opinions and comments may have been previously posted @BioDueDiligence, at www.biotechduediligence.com, or disseminated to Chimera Research Group subscribers.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today